EP2542589A4 - Anticorps et compositions anti-her2 - Google Patents

Anticorps et compositions anti-her2

Info

Publication number
EP2542589A4
EP2542589A4 EP11750275.7A EP11750275A EP2542589A4 EP 2542589 A4 EP2542589 A4 EP 2542589A4 EP 11750275 A EP11750275 A EP 11750275A EP 2542589 A4 EP2542589 A4 EP 2542589A4
Authority
EP
European Patent Office
Prior art keywords
compositions
her2 antibodies
her2
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11750275.7A
Other languages
German (de)
English (en)
Other versions
EP2542589A1 (fr
Inventor
Mikkel Wandahl Pedersen
Allan Jensen
Per-Johan Meijer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Symphogen AS
Original Assignee
Symphogen AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen AS filed Critical Symphogen AS
Publication of EP2542589A1 publication Critical patent/EP2542589A1/fr
Publication of EP2542589A4 publication Critical patent/EP2542589A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP11750275.7A 2010-03-04 2011-03-03 Anticorps et compositions anti-her2 Withdrawn EP2542589A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31055210P 2010-03-04 2010-03-04
DKPA201070085 2010-03-04
US35413310P 2010-06-11 2010-06-11
US201061428014P 2010-12-29 2010-12-29
PCT/IB2011/050903 WO2011107957A1 (fr) 2010-03-04 2011-03-03 Anticorps et compositions anti-her2

Publications (2)

Publication Number Publication Date
EP2542589A1 EP2542589A1 (fr) 2013-01-09
EP2542589A4 true EP2542589A4 (fr) 2013-08-07

Family

ID=44541704

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11750275.7A Withdrawn EP2542589A4 (fr) 2010-03-04 2011-03-03 Anticorps et compositions anti-her2

Country Status (5)

Country Link
EP (1) EP2542589A4 (fr)
JP (1) JP6039428B2 (fr)
CN (1) CN102884084B (fr)
TW (1) TW201141519A (fr)
WO (1) WO2011107957A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2337800B1 (fr) 2008-09-15 2013-10-02 Yeda Research and Development Co. Ltd. Combinaisons d'anticorps et utilisation de celles-ci pour traiter le cancer
DK2635604T3 (en) 2010-11-01 2017-02-27 Symphogen As PAN-HER-ANTIBODY COMPOSITION
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
WO2012156975A1 (fr) * 2011-05-16 2012-11-22 Yeda Research And Development Co. Ltd. Associations d'anticorps anti-erbb pour le traitement du cancer
MX358728B (es) 2012-05-02 2018-09-03 Symphogen As Composiciones de anticuerpos pan-receptor del factor de crecimiento epidermico humano (pan-her) humanizados.
MX362456B (es) 2012-08-24 2019-01-18 Univ California Anticuerpos y vacunas para utilizarse en el tratamiento de canceres por ror1 y para inhibir la metastasis.
RU2656161C1 (ru) * 2013-11-19 2018-05-31 Ремеджен, Лтд. Анти-неr2 антитело и его конъюгат
CN104974261B (zh) * 2014-04-01 2019-06-14 三生国健药业（上海）股份有限公司 重组抗her2/ps双特异性抗体、其制备方法和应用
KR20170094787A (ko) * 2014-12-18 2017-08-21 에프. 호프만-라 로슈 아게 Cdc 유발 항체를 측정하기 위한 검정 및 방법
CN106831987B (zh) * 2015-12-04 2020-01-21 浙江大学 一种抗人her2抗体及其编码基因和应用
JP2019525138A (ja) * 2016-06-16 2019-09-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｄｃを誘発する抗体を決定するためのアッセイ法および方法
IL299099A (en) 2016-06-27 2023-02-01 Univ California Combinations of cancer treatments
CN107137424A (zh) * 2017-05-15 2017-09-08 广州领晟医疗科技有限公司 一种利用正常小鼠建立her2阳性肿瘤的动物模型的方法
CA3093477A1 (fr) * 2018-03-13 2019-09-19 Zymeworks Inc. Conjugues anticorps anti-her2 biparatopique-medicament et procedes d'utilisation
CN109134656A (zh) * 2018-09-12 2019-01-04 四川妙和生物科技有限公司 一种抗her2多克隆抗体
CN113646332B (zh) * 2019-03-15 2024-08-23 公益财团法人癌研究会 抗平足蛋白抗体
EP3941947A4 (fr) * 2019-03-22 2022-12-14 Olivia Newton-John Cancer Research Institute Molécules de liaison anti-her2

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004048525A2 (fr) * 2002-11-21 2004-06-10 Genentech, Inc. Therapie de maladies ou troubles benins a l'aide d'anticorps anti-erbb2
WO2010022736A2 (fr) * 2008-08-29 2010-03-04 Symphogen A/S Compositions de l'anticorps de recombinaison anti-récepteur du facteur de croissance anti-épidermique egfr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794128B2 (en) * 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
US7244826B1 (en) * 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
GB0503546D0 (en) * 2005-02-21 2005-03-30 Hellenic Pasteur Inst Antibody
US7498142B2 (en) * 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004048525A2 (fr) * 2002-11-21 2004-06-10 Genentech, Inc. Therapie de maladies ou troubles benins a l'aide d'anticorps anti-erbb2
WO2010022736A2 (fr) * 2008-08-29 2010-03-04 Symphogen A/S Compositions de l'anticorps de recombinaison anti-récepteur du facteur de croissance anti-épidermique egfr

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COYNE C P ET AL: "Dual potency anti-HER2/neu and anti-EGFR anthracycline immunoconjugates in chemotherapeutic-resistant mammary carcinoma combined with cyclosporin A and verapamil P-glycoprotein inhibition", JOURNAL OF DRUG TARGETING, HARWOOD ACADEMIC PUBLISHERS GMBH, DE, vol. 17, no. 6, 1 July 2009 (2009-07-01), pages 474 - 489, XP008149521, ISSN: 1061-186X, DOI: 10.1080/10611860903012802 *
HUHALOV ALEXANDRA ET AL: "MM-111, an ErbB2/ErbB3 bispecific antibody with potent activity in ErbB2-overexpressing cells, positively combines with trastuzumab to inhibit growth of breast cancer cells driven by the ErbB2/ErbB3 oncogenic unit", AMERICAN ASSOCIATION FOR CANCER RESEARCH. PROCEEDINGS OF THE ANNUAL MEETING, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 51, 1 April 2010 (2010-04-01), pages 845 - 846, XP009145436, ISSN: 0197-016X *
NAHTA R ET AL: "The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 64, no. 7, 1 April 2004 (2004-04-01), pages 2343 - 2346, XP002378994, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-03-3856 *
See also references of WO2011107957A1 *

Also Published As

Publication number Publication date
CN102884084A (zh) 2013-01-16
JP2013520984A (ja) 2013-06-10
JP6039428B2 (ja) 2016-12-07
CN102884084B (zh) 2016-12-07
WO2011107957A1 (fr) 2011-09-09
EP2542589A1 (fr) 2013-01-09
TW201141519A (en) 2011-12-01

Similar Documents

Publication Publication Date Title
EP2542589A4 (fr) Anticorps et compositions anti-her2
IL271305B (en) Anti-ntb–a antibodies and related compositions and methods
HK1216540A1 (zh) 抗體及其用途
IL225954B (en) Anti-her3 antibodies and preparations
AP4082A (en) Anti-cd40 antibodies
ZA201209004B (en) Anti-fgfr2 antibodies
GB201000467D0 (en) Antibodies
IL221371A0 (en) Anti-lrp6 antibodies
RS62700B1 (sr) Anti-cd277 antitela i njihove upotrebe
EP2636736A4 (fr) Nouvel anticorps anti-dr5
HK1194388A1 (zh) 抗缺刻蛋白 抗體
GB201020738D0 (en) Antibodies
PT2603528T (pt) Anticorpos glicosilados em fab
EP2746394A4 (fr) Anticorps et composition le contenant
GB201002238D0 (en) Antibodies
EP2588141A4 (fr) Formulations d'anticorps
EP2593475A4 (fr) Anticorps monoclonal anti-addl et ses utilisations
PL2621955T3 (pl) Przeciwciała anty-CEACAM6 i ich zastosowania
EP2632952A4 (fr) Anticorps anti-sod1 et utilisations de ceux-ci
ZA201302459B (en) Antibodies
ZA201300804B (en) Anti-vegfr-3 antibody compositions
LT2797579T (lt) Kompozicija, apimanti anti-gliuteno antikūnus ir taninus
EP2545378A4 (fr) Anticorps anti-lg3 et leurs utilisations
GB201020751D0 (en) Antibodies
GB201005062D0 (en) Antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20121004

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130705

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/30 20060101AFI20130701BHEP

Ipc: A61K 39/00 20060101ALI20130701BHEP

17Q First examination report despatched

Effective date: 20140409

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20141021